Canada - English - Health Canada

pharmascience inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

auro pharma inc - tofacitinib (tofacitinib citrate) - tablet - 10mg - tofacitinib (tofacitinib citrate) 10mg

Canada - English - Health Canada

auro pharma inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

apotex inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

apotex inc - tofacitinib (tofacitinib citrate) - tablet - 10mg - tofacitinib (tofacitinib citrate) 10mg

Canada - English - Health Canada

taro pharmaceuticals inc - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

Canada - English - Health Canada

taro pharmaceuticals inc - tofacitinib (tofacitinib citrate) - tablet - 10mg - tofacitinib (tofacitinib citrate) 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tofacitinib citrate, quantity: 8.078 mg (equivalent: tofacitinib, qty 5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3350 - rheumatoid arthritis (ra),xeljanz is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. xeljanz can be used alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (dmards), including methotrexate. psoriatic arthritis (psa),xeljanz in combination with conventional synthetic dmards is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to a prior dmard therapy. ulcerative colitis (uc),xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.,ankylosing spondylitis (as),xeljanz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.,juvenile idiopathic arthritis (jia),xeljanz is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis, extended oligoarthritis and systemic juvenile arthritis without systemic features for six months) and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with dmards.

Canada - English - Health Canada

jamp pharma corporation - tofacitinib (tofacitinib citrate) - tablet - 5mg - tofacitinib (tofacitinib citrate) 5mg

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - tofacitinib citrate (unii: o1ff4div0d) (tofacitinib - unii:87la6fu830) - tofacitinib 5 mg - xeljanz/xeljanz xr is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (ra) who have had an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz xr is indicated for the treatment of adult patients with active psoriatic arthritis (psa) who have had an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz xr is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have had an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz xr is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc), who have an inadequate response or intolerance to one or more tnf blockers. xeljanz/xeljanz oral solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcjia) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more tnf